

Hemophilia Gene Therapy-EMEA Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/H7E2EAA1678MEN.html

Date: March 2018 Pages: 130 Price: US\$ 3,480.00 (Single User License) ID: H7E2EAA1678MEN

Abstracts

Report Summary

Hemophilia Gene Therapy-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Hemophilia Gene Therapy industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Hemophilia Gene Therapy 2013-2017, and development forecast 2018-2023 Main market players of Hemophilia Gene Therapy in EMEA, with company and product

introduction, position in the Hemophilia Gene Therapy in EMEA, with company and product

Market status and development trend of Hemophilia Gene Therapy by types and applications

Cost and profit status of Hemophilia Gene Therapy, and marketing status Market growth drivers and challenges

The report segments the EMEA Hemophilia Gene Therapy market as:

EMEA Hemophilia Gene Therapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023): Europe Middle East Africa

EMEA Hemophilia Gene Therapy Market: Product Type Segment Analysis



(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023): Hemophilia A Hemophilia B Others

EMEA Hemophilia Gene Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis) Hospital Clinic

EMEA Hemophilia Gene Therapy Market: Players Segment Analysis (Company and Product introduction, Hemophilia Gene Therapy Sales Volume, Revenue, Price and Gross Margin): Novo Nordisk A/S Pfizer Inc. F. Hoffmann-La Roche Ltd. Bayer AG Shire plc CSL Limited Octapharma AG Grifols International SA Swedish Orphan Biovitrum AB Alnylam Pharmaceuticals, Inc.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF HEMOPHILIA GENE THERAPY

- 1.1 Definition of Hemophilia Gene Therapy in This Report
- 1.2 Commercial Types of Hemophilia Gene Therapy
- 1.2.1 Hemophilia A
- 1.2.2 Hemophilia B
- 1.2.3 Others
- 1.3 Downstream Application of Hemophilia Gene Therapy
- 1.3.1 Hospital
- 1.3.2 Clinic
- 1.4 Development History of Hemophilia Gene Therapy
- 1.5 Market Status and Trend of Hemophilia Gene Therapy 2013-2023
- 1.5.1 EMEA Hemophilia Gene Therapy Market Status and Trend 2013-2023
- 1.5.2 Regional Hemophilia Gene Therapy Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Hemophilia Gene Therapy in EMEA 2013-2017
- 2.2 Consumption Market of Hemophilia Gene Therapy in EMEA by Regions
- 2.2.1 Consumption Volume of Hemophilia Gene Therapy in EMEA by Regions
- 2.2.2 Revenue of Hemophilia Gene Therapy in EMEA by Regions
- 2.3 Market Analysis of Hemophilia Gene Therapy in EMEA by Regions
- 2.3.1 Market Analysis of Hemophilia Gene Therapy in Europe 2013-2017
- 2.3.2 Market Analysis of Hemophilia Gene Therapy in Middle East 2013-2017
- 2.3.3 Market Analysis of Hemophilia Gene Therapy in Africa 2013-2017
- 2.4 Market Development Forecast of Hemophilia Gene Therapy in EMEA 2018-20232.4.1 Market Development Forecast of Hemophilia Gene Therapy in EMEA 2018-2023

2.4.2 Market Development Forecast of Hemophilia Gene Therapy by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
- 3.1.1 Consumption Volume of Hemophilia Gene Therapy in EMEA by Types
- 3.1.2 Revenue of Hemophilia Gene Therapy in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe



- 3.2.2 Market Status by Types in Middle East
- 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Hemophilia Gene Therapy in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Hemophilia Gene Therapy in EMEA by Downstream Industry4.2 Demand Volume of Hemophilia Gene Therapy by Downstream Industry in MajorCountries

4.2.1 Demand Volume of Hemophilia Gene Therapy by Downstream Industry in Europe

4.2.2 Demand Volume of Hemophilia Gene Therapy by Downstream Industry in Middle East

4.2.3 Demand Volume of Hemophilia Gene Therapy by Downstream Industry in Africa4.3 Market Forecast of Hemophilia Gene Therapy in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF HEMOPHILIA GENE THERAPY

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Hemophilia Gene Therapy Downstream Industry Situation and Trend Overview

CHAPTER 6 HEMOPHILIA GENE THERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

6.1 Sales Volume of Hemophilia Gene Therapy in EMEA by Major Players

- 6.2 Revenue of Hemophilia Gene Therapy in EMEA by Major Players
- 6.3 Basic Information of Hemophilia Gene Therapy by Major Players

6.3.1 Headquarters Location and Established Time of Hemophilia Gene Therapy Major Players

6.3.2 Employees and Revenue Level of Hemophilia Gene Therapy Major Players6.4 Market Competition News and Trend

- 6.4.1 Merger, Consolidation or Acquisition News
- 6.4.2 Investment or Disinvestment News
- 6.4.3 New Product Development and Launch

CHAPTER 7 HEMOPHILIA GENE THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA



- 7.1 Novo Nordisk A/S
 - 7.1.1 Company profile
 - 7.1.2 Representative Hemophilia Gene Therapy Product

7.1.3 Hemophilia Gene Therapy Sales, Revenue, Price and Gross Margin of Novo Nordisk A/S

7.2 Pfizer Inc.

7.2.1 Company profile

7.2.2 Representative Hemophilia Gene Therapy Product

- 7.2.3 Hemophilia Gene Therapy Sales, Revenue, Price and Gross Margin of Pfizer Inc.
- 7.3 F. Hoffmann-La Roche Ltd.
- 7.3.1 Company profile
- 7.3.2 Representative Hemophilia Gene Therapy Product
- 7.3.3 Hemophilia Gene Therapy Sales, Revenue, Price and Gross Margin of F.

Hoffmann-La Roche Ltd.

7.4 Bayer AG

7.4.1 Company profile

- 7.4.2 Representative Hemophilia Gene Therapy Product
- 7.4.3 Hemophilia Gene Therapy Sales, Revenue, Price and Gross Margin of Bayer AG

7.5 Shire plc

7.5.1 Company profile

- 7.5.2 Representative Hemophilia Gene Therapy Product
- 7.5.3 Hemophilia Gene Therapy Sales, Revenue, Price and Gross Margin of Shire plc

7.6 CSL Limited

7.6.1 Company profile

7.6.2 Representative Hemophilia Gene Therapy Product

7.6.3 Hemophilia Gene Therapy Sales, Revenue, Price and Gross Margin of CSL Limited

7.7 Octapharma AG

7.7.1 Company profile

7.7.2 Representative Hemophilia Gene Therapy Product

7.7.3 Hemophilia Gene Therapy Sales, Revenue, Price and Gross Margin of Octapharma AG

7.8 Grifols International SA

7.8.1 Company profile

7.8.2 Representative Hemophilia Gene Therapy Product

7.8.3 Hemophilia Gene Therapy Sales, Revenue, Price and Gross Margin of Grifols International SA

7.9 Swedish Orphan Biovitrum AB



7.9.1 Company profile

7.9.2 Representative Hemophilia Gene Therapy Product

7.9.3 Hemophilia Gene Therapy Sales, Revenue, Price and Gross Margin of Swedish Orphan Biovitrum AB

7.10 Alnylam Pharmaceuticals, Inc.

7.10.1 Company profile

7.10.2 Representative Hemophilia Gene Therapy Product

7.10.3 Hemophilia Gene Therapy Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals, Inc.

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HEMOPHILIA GENE THERAPY

- 8.1 Industry Chain of Hemophilia Gene Therapy
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF HEMOPHILIA GENE THERAPY

- 9.1 Cost Structure Analysis of Hemophilia Gene Therapy
- 9.2 Raw Materials Cost Analysis of Hemophilia Gene Therapy
- 9.3 Labor Cost Analysis of Hemophilia Gene Therapy
- 9.4 Manufacturing Expenses Analysis of Hemophilia Gene Therapy

CHAPTER 10 MARKETING STATUS ANALYSIS OF HEMOPHILIA GENE THERAPY

- 10.1 Marketing Channel
- 10.1.1 Direct Marketing
- 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
- 10.2.2 Brand Strategy
- 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION



CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Hemophilia Gene Therapy-EMEA Market Status and Trend Report 2013-2023 Product link: <u>https://marketpublishers.com/r/H7E2EAA1678MEN.html</u>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/H7E2EAA1678MEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970